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Abstract
Bladder cancer is one of the most common genitourinary neoplasms in industrialized countries. Multifocality and high
recurrence rates are prominent clinical features of this disease and contribute to its high morbidity. Therefore, more
sensitive and less invasive techniques could help identify individuals with asymptomatic disease. In this context, we used
the micronucleus assay to evaluate whether cytogenetic alterations could be used as biomarkers for monitoring patients
with a history of urothelial cell carcinoma (UCC). We determined the frequency of micronucleated urothelial cells (MNC) in
exfoliated bladder cells from 105 patients with (n = 52) or without (n = 53) a history of UCC, all of whom tested negative for
neoplasia by cytopathological and histopathological analyses. MNC frequencies were increased in patients with a history of
UCC (non-smoker and smoker/ex-smoker patients vs non-smoker and smoker/ex-smoker controls; p,0.001), in non-smoker
UCC patients (vs non-smoker controls; p,0.01), and in smoker/ex-smoker controls (vs non-smoker controls; p,0.001).
Patients with a history of recurrent disease also demonstrated a higher MNC frequency compared to patients with non-
recurrent neoplasia. However, logistic regression using smoking habits, age and gender as confounding factors did not
confirm MNC frequency as a marker for UCC recurrence. Fluorescent in situ hybridization analysis (using a pan-centromeric
probe) showed that micronuclei (MN) arose mainly from clastogenic events regardless of UCC and/or smoking histories. In
conclusion, our results confirm previous indications that subjects with a history of UCC harbor genetically unstable cells in
the bladder urothelium. Furthermore, these results support using the micronucleus assay as an important tool for
monitoring patients with a history of UCC and tumor recurrence.
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Introduction
Bladder cancer is one of the most common genitourinary
neoplasms in industrialized countries, and cigarette smoking is the
main risk factor for this disease, as smokers have an approximate
3-fold increased risk of disease [1]. Urothelial cell carcinomas
(UCC) account for 90% of all urinary bladder tumors, and
multifocality and high recurrence rates are important clinical
features of this disease [2,3]. Another critical feature of UCC is the
high morbidity associated with the periodic surgical procedures
required to investigate tumor recurrence and eventual resection
[4]. Tumor grade, stage, size, and multifocality may predict
progression and recurrence, although in some patients, these
variables fail to accurately predict progression and recurrence
because tumors of similar grade and stage can still differ
significantly in their biology [5]. The development of cytogenetic
markers has increased the sensitivities of UCC diagnosis and
prognosis, but the precise characterization of atypical urinary cells
remains a challenge for pathologists, especially in cases of low-
grade tumors [6].
Cancer cells typically harbor chromosomal alterations, such as
aneuploidy or polyploidy and abnormal chromosome structures
[7]. The micronuclei (MN) frequency is a widely used biomarker
for chromosome instability [8–13]. MN are chromosome frag-
ments or whole chromosomes that are not incorporated into
daughter nuclei during cell division [8], and the frequency of
micronucleated cells (MNC) may predict cancer risk, suggesting
that increased MN formation may be associated with early
carcinogenic events [9]. Indeed, one retrospective study reported
an increased MN frequency in urinary cytology smears from
samples that were initially diagnosed as ‘‘atypical urothelial cells’’
but later determined to be malignant cells upon follow-up
histopathological analysis [10]. These findings strengthen the
notion that MN scoring could be used in cytopathological analyses
to assist in the proper diagnosis of these cases [10]. We have
previously shown that genetic instability could be detected in
urothelial cells, even before cellular atypia was detectable by
cytology [13]. In this previous study, increased MNC frequencies
were observed in normal urothelial cells obtained from bladder
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washings of patients with a history of UCC and/or smoking, but
this increase was not statistically significant when compared to
urothelial cells from a control population, which was likely due to
the relatively small sample size [13]. This finding, together with
recent data from Arora et al. [10], prompted us to investigate the
utility of a MN assay to detect genetic instability in urothelial cells
with normal cytology in a new and larger cohort of patients with
recurrent UCC. Finally, to improve our understanding of the
genetic mechanisms involved in UCC, we also performed
fluorescent in situ hybridization (FISH) in urothelial cells using a
human pan-centromeric probe to gain insight into the mechanism
by which MN originate in these cells.
Materials and Methods
1. Subjects
This study was approved by the Ethics Committee for Human
Research of Botucatu Medical School, UNESP (Document No
276/2005-CEP), and signed informed consent was obtained from
all subjects recruited for the present study.
The screening for micronucleated urothelial cells (hereafter
referred to as MNCs) was conducted on 52 patients (43 males
and 9 females) with a history of UCC and a negative
cytopathological diagnosis for neoplasia. The reference group
(controls) consisted of 53 patients (32 males and 21 females) with
no history of UCC who were scheduled for cystoscopy to
investigate other urinary tract complaints (e.g., hematuria,
dysuria, pollakiuria, nocturia, vesical and kidney stones, cystitis,
neurogenic bladder). UCC history was confirmed from previous
positive biopsies, cytological analyses, and medical records.
Tumors were classified as low or high grade according to the
WHO classification [14]. The UCC patient and control groups
were aged 38–89 years and 35–81 years, respectively. The
studied population included 3 self-identified ethnic groups, as
defined by The Brazilian Institute of Geography and Statistics
[15]: white (96.4%), yellow (Asians; 1.8%), and brown (mixed
race; 1.8%). Both the patient and control groups were randomly
recruited at the Clinical Hospital in Botucatu, São Paulo State
(22u53909?S, 48u26942?W). The city of Botucatu is a Schistosoma
haematobium non-endemic region. Personal data for all individuals
were recorded in a detailed questionnaire that was administered
immediately before or after cystoscopy. The collected data
included ethnicity, age, gender, smoking and alcohol consump-
tion habits, medical data, and histories of relevant exposures to
organic solvents, dyes, diesel exhaust, pesticides, and X-ray
radiation. Subjects were considered smokers if they smoked at
least 100 cigarettes in their life and currently smoke every day or
some days; ex-smokers were subjects who had stopped smoking
at least 1 year prior to sample collection [16]. Alcohol
consumption was classified in 3 subjective categories [13]: non-
drinker, defined as no alcohol consumption or social drinking;
mild drinker, defined as the consumption up to 1 cup (,3.4 fl.
oz) of an alcoholic beverage per day or more than 1 cup on
weekends; or heavy drinker, defined as the consumption of more
than 1 L of a light alcoholic beverage (beer, wine, or cider) or 2
cups of hard liquor (Brazilian cachaça, vodka, or whiskey) per
day for at least 6 years. Subjects were considered ‘‘exposed to
toxic substances’’ (pesticides, solvents, and diesel exhaust) if they
were occupationally exposed or had been exposed for at least
2 years [13].
2. Bladder washes
Bladder washes (bladder barbotage) were obtained by intraves-
ical administration of a 0.9% saline solution. Two aliquots of
15 mL were collected per patient; one of the aliquots was
subjected to Giemsa staining for MN examination, and the other
was used for FISH. For Giemsa staining, bladder washing samples
were centrifuged at 1,500 rpm for 10 min, and 200 mL of the
obtained cell suspensions were cytocentrifuged at 1,400 rpm for
10 min. For FISH, 200 mL of the cell suspensions were fixed
3 times in a methanol: acetic acid (3:1) solution. Slides were stored
at room temperature for 2 weeks and then at 220uC until staining
and analysis.
3. Micronucleus test
The frequency of MNCs in 5% Giemsa-stained slides was
determined by light microscopy at a magnification of 1,0006
following the criteria established by Lehucher-Michel et al. [12].
Those subjects with frequencies of Giemsa-stained MNCs above
1% were selected for FISH MN scoring. The probes used for all
human centromeres were directly labeled with FITC
(PAHC0001-G, Qbiogene, USA), and FISH slides were pro-
cessed according to the probe manufacturer’s protocol with slight
modifications. After the hybridization step, DAPI in antifade
solution was used to counterstain DNA (Vector Laboratories,
USA), which enabled the simultaneous observation of the total
DNA and hybridization signals. MN were examined for
fluorescence using a fluorescence microscope at 1,0006 magni-
fication with the Case Data Manager software (Applied Spectral
Imaging, CA, USA). Cells with non-FITC-labeled MN (centro-
mere-negative MN; MNC2) were assumed to contain acentric
chromosome fragments (Figure 1a), whereas FITC-labeled MN
(centromere-positive MN; MNC+) contained whole chromo-
somes (Figure 1b). The frequencies of MNC, MNC+, and
MNC2 cells per 1,000 cells were calculated for each subject.
Due to the large number of degenerate and occasionally scarce
urothelial cells, the number of cells analyzed by Giemsa staining
ranged from 500 to 1,000 (n = 17, 500–700 cells; n = 21, 701–
999; n = 67, 1,000 cells) per subject. For FISH analysis, the
number of analyzed cells also ranged from 500 to 1,000 (n = 4,
500–700 cells; n = 2, 701–999; n = 31, 1000 cells).
4. Statistical analysis
The number of urothelial cells and MNC were adjusted
according to a generalized linear model that considered the MN
frequency (MNC, MNC+, and MNC2) as the dependent variable.
A binomial distribution was used to adjust the model to consider
UCC history, smoking history, and the interaction between UCC
Figure 1. FISH-stained urothelial cells with probes for all
chromosome centromeres (green spots). a) Urothelial cells
counterstained with DAPI, and the red arrow indicates a micronucleus
(MN) with no centromeric signal (MNC2). b) Urothelial cells counter-
stained with DAPI, and the yellow arrow indicates a MN with
centromeric signal (MNC+). Photomicrographs were acquired at
1,0006magnification.
doi:10.1371/journal.pone.0086162.g001
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and smoking history. The same model was adjusted for gender,
age, number of cigarettes per day, duration of smoking, alcohol
consumption, and toxic substance exposure. Logistic regression
analysis adjusted for demographic variables was used to provide an
estimated risk for tumor recurrence in relation to MN frequency.
The associations between tumor invasiveness, tumor grade, and
tumor recurrence in patients with and without a history of
smoking were analyzed using the chi square test. Comparisons of
the simple frequencies of gender, tumor invasiveness, tumor grade,
tumor recurrence, alcohol consumption, and toxic substance
exposure were performed using the test of proportions. All
analyses were performed using SAS for Windows (v. 9.2), and a
p value,0.05 was considered significant.
Results
The demographic and medical data are presented in Table 1.
The number of males (n = 43; 82.7%) with a history of UCC was
significantly higher (p,0.05) than the corresponding number of
females (n = 9; 17.3%). For male and female patients, the average
age was 67.8613.3 years (35–89 years); 31 (59.6%) patients were
smokers or ex-smokers, and 21 (40.4%) were non-smokers. No
statistically significant differences were observed in the number of
non-smoker and smoker/ex-smoker patients. Similarly, there was
no statistically significant difference between the number of
patients with a history of high-grade (n = 23, 44.2%) or low-grade
tumors (n = 29, 55.8%), even when considering smoking habits







Number of subjects1 29 (54.7) 24 (45.3) 53 21 (40.4) 31 (59.6) 52
Gender2 Male 55.2 66.7 60.4 71.4 90.3 82.7*
Female 44.8 33.4 39.6 28.6 9.7 17.3
Age (years)2 59.2614.2 57.6613.2 58.5613.6 67.2616.4 68.3610.9 67.8613.3
Cigarettes/day3 - 19610 - - 26614 -
Tumor grade2 High - - - 38.1 48.4 44.2
Low - - - 61.9 51.6 55.8
Tumor invasiveness2 Invasive - - - 23.8 32.3 28.8**
Non-invasive - - - 76.2 67.7 71.2
Tumor recurrence2 Recurrent - - - 85.7 74.2 78.8#
Non-recurrent - - - 14.3 25.8 21.2
Alcohol consumption 1;4 Non-drinker 19 (65.5) 19 (79.2) 38 (71.7) 18 (85.7) 17 (54.8) 35 (67.3)
Mild drinker 2 (6.9) 2 (8.3) 4 (7.5) 1 (4.8) 7 (22.6) 8 (15.4)
Heavy drinker 2 (6.9) 2 (8.3) 4 (7.5) 0 (0) 5 (16.1) 5 (9.6)
Toxic substance
exposure 1;5
Solvents 2 (6.9) 8 (33.3) 10 (18.9) 2 (9.5) 8 (25.8) 10 (19.2)
Pesticide 6 (20.7) 7 (29.2) 13 (24.5) 8 (38.1) 6 (19.3) 14 (26.9)
Diesel 1 (3.5) 1 (4.2) 2 (3.8) 1 (4.8) 4 (12.9) 5 (9.6)
UCC, patients with history of urothelial cell carcinoma; 1 No. (%); 2 data are presented as percentages (%); 3 mean 6 standard deviation; * p,0.05, compared to female
patients; ** p,0.01, compared to non-invasive tumors; # p,0.001, compared to non-recurrent tumors; 4 data not available for 7 controls (6 non-smokers and 1 smoker/
ex-smoker) and 4 UCC patients (2 non-smokers and 2 smokers/ex-smokers); 5 data not available for 1 smoker/ex-smoker control and 6 UCC patients (2 non-smokers and
4 smokers/ex-smokers).
doi:10.1371/journal.pone.0086162.t001
Table 2. Urothelial MNC frequency in subjects with and without a history of bladder UCC.
Groups Number of subjects Number of cells analyzed Number of MNC % MNC1 p value
Control 53 54,804 107 1.9 -
Non-smokers 29 30,639 40 1.3 -
Smokers/ex-smokers 24 24,165 67 2.8a ,0.001a
UCC 52 44,949 135 3.0b ,0.001b
Non-smokers 21 19,052 70 3.7c,d ,0.05c, ,0.001d
Smokers/ex-smokers 31 25,897 65 2.5e,f ,0.01e, .0.05f
1MNC per 1,000 cells; a, smoker/ex-smoker controls vs. non-smoker controls; b, UCC patients (non-smokers + smokers/ex-smokers) vs. controls (non-smokers + smokers/
ex-smokers); c, non-smoker UCC patients vs. smoker/ex-smoker UCC patients; d, non-smoker UCC patients vs. non-smoker controls; e, smoker/ex-smoker UCC patients
vs. non-smoker controls; f, smoker/ex-smoker UCC patients vs. smoker/ex-smoker controls.
doi:10.1371/journal.pone.0086162.t002
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(p.0.05). Regardless of smoking history, the number of subjects
diagnosed with invasive tumors (n = 15, 28.8%) was significantly
lower compared to the number of subjects with non-invasive
tumors (n = 37, 71.2%) (p,0.01). Additionally and regardless of
smoking history, the number of patients with recurrent tumors
was significantly higher (n = 41, 78.8%) than the number of
patients with non-recurrent tumors (n = 11, 21.2%) (p,0.001).
Regarding alcohol consumption and exposure to toxic substanc-
es, no significant difference was detected between UCC patients
and controls (p.0.05). In the control group, 32 (60.4%) patients
were male, and 21 (39.6%) female; 29 (57.4%) patients were non-
smokers, and 24 (45.3%) were smokers or ex-smokers. The
average age was 58.5613.6 years (35–82 years).
The MNC frequency (3.0%) in patients with a history of UCC
was significantly higher (p,0.001) than the frequency in the
control group (1.9%) (Table 2). However, when considering
smoking history, a statistically significant (p,0.001) difference was
detected only between non-smoker UCC patients (3.7%) and non-
smoker controls (1.3%). In both the UCC patient and control
groups, a statistically significant difference was observed between
non-smokers and smokers/ex-smokers (Table 2). Indeed, it is
important to notice that there was no statistically significant
difference in the MNC frequency of smokers/ex-smokers from the
UCC group, when compared with the control group (p.0.05). No
interference was observed in MNC frequencies when alcohol
consumption and toxic substance exposure were included in the
binomial analysis.
FISH data were obtained from 37 subjects (21 UCC patients
and 16 controls) with greater than 1% Giemsa-stained MNC.
Although the binomial analyses demonstrated significant differ-
ences, data were interpreted qualitatively because of the low
number of MNC+ and MNC2 samples. Overall, 75% (range,
66.6–81.5%) of the scored MNC samples stained negative for
centromeres (MNC2). In fact, the largest increase in MNC2
status compared to centromere-positive MNCs (MNC+) was
observed for smoker/ex-smoker UCC patients (81.5% MNC2
vs. 18.5% MNC+) (Table 3).
When demographic and clinical features were considered
(Table 4), significant (p,0.05) interference was detected in MNC
frequency for age and tumor recurrence status in the UCC patient
group. Patients older than 60 years showed higher MNC
frequencies compared to patients less than 60 years of age
(3.5% vs. 2.1%, respectively; p,0.05); patients with recurrent
tumors also had higher MNC frequencies compared to patients
with non-recurrent tumors (3.4% vs. 1.7%, respectively; p,0.05).
Importantly, 70.3% of patients with recurrent tumors (n = 29)
were older than 60 years of age. In addition, logistic regression
analysis did not reveal a relationship between high MNC
frequencies and increased tumor recurrence risk in smokers/ex-
smokers UCC patients (p.0.05). Age, gender and smoking habit
were considered as potential confounding factors in the regression
model.
Discussion
In this study, we used the micronucleus test to evaluate
chromosomal damage in patients with a history of UCC, in an
attempt to introduce this test as an auxiliary biomarker for bladder
cancer monitoring. We observed a significant increase in MNC
Table 3. Frequencies of centromere-positive (MNC+) and
centromere-negative (MNC2) urothelial MNCs from subjects
with and without a history of bladder UCC.
Groups
Number of




Control 16 14,783 20 5 (25) 15 (75)
Non-smokers 8 7,229 4 1 (25) 3 (75)
Smokers/ex-
smokers
8 7,554 16* 4 (25) 12* (75)
UCC 21 20,150 39 9 (23.1) 30** (76.9)
Non-smokers 8 8,000 12 4 (33.3) 8 (66.6)
Smokers/ex-
smokers
13 12,150 27 5 (18.5) 22** (81.5)
1MNC, micronucleated urothelial cells; *p,0.05, compared to non-smoker
controls; **p,0.01, compared to % MNC+ within the UCC group.
doi:10.1371/journal.pone.0086162.t003
Table 4. Urothelial MNC frequency (Giemsa staining) in subjects with and without a history of UCC stratified according to
demographic, histological and clinical variables.
Variables Number of subjects % MNC
1
Control UCC Control UCC
Gender male 32 43 1.8 2.8
female 21 9 2.2 3.8
Age #60 years old (35–60 years) 29 16 1.9 2.1
.60 years old (61–89 years) 24 36** 1.9 3.5*
Tumor grade low grade - 29 - 2.9
high grade - 23 - 3.2
Tumor recurrence2 non-recurrent - 11 - 1.7
recurrent - 41 - 3.4
Tumor invasiveness non-invasive - 37 - 3.1
invasive - 15 - 2.7
1MNC – micronucleated cells per 1000 cells; *p,0.05, compared to UCC patients less than 60 years of age; 2 Logistic regression analysis (considering smoking habit, age
and gender as confounding factors) did not show significant difference, p.0.05.
doi:10.1371/journal.pone.0086162.t004
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frequency in patients with a history of UCC, but with cytological
and histopathological diagnoses negative for neoplasia. Our data
both corroborate and bring statistical support to the trend of
increased MN in UCC, which we previously detected in an
independent study with a smaller group of patients with a history
of UCC [13]. Furthermore, the present data are highly consistent
with increased levels of primary DNA damage and aneuploidy,
which we previously detected using the alkaline single-cell gel
(comet) assay [13]. Similarly, a recent study reported p53 protein
expression in more than 25% of exfoliated urothelial cells from
histologically normal urothelium of patients with a history of
UCC, which also indicates that this ‘‘normal’’ urothelium is
genomically unstable [17]. Additionally, urothelial cells were also
analyzed for chromosomal aberrations using high-resolution
comparative genomic hybridization and, they did not find
numerical alterations of the chromosomes 7, 17 and 9p21 regions,
but did find high frequencies of gains in 11p12 and losses in 16p12
[17]. It is important to emphasize that an increased MNC
frequency was not predictive of UCC recurrence when a logistic
regression was carried out including age, gender and smoking
habits as confounding factors. Therefore, taken together our data
strongly support the idea that genetic instability can be detected
prior to a diagnosis of cellular atypia and highlight MN
examination as an important tool for monitoring patients with a
history of UCC and recurrent tumors.
To gain insight into the mechanism of MN formation in
cytologically normal urothelial cells from patients with a history of
UCC, we used FISH with a pan-centromeric probe to evaluate
aneugenic and clastogenic events. In the control and UCC patient
groups, the frequencies of centromere negative MN (MNC2) were
consistently higher than the frequencies of centromere positive
MN (MNC+). This result suggested that MN mainly arose from
chromosomal, and that this tendency was either stabilized or
mildly exacerbated in patients with a history of UCC. In fact, Del
Rey et al. [18] suggested that MN resulting from acentric
fragments (chromosome breakage or cyclin D1 gene amplification)
or from whole chromosomes might contribute to genomic
instability in UCC tumor samples. Similarly, a high frequency of
acentromeric MN was observed in the peripheral lymphocytes of
patients with different types of cancer prior to treatment [11].
Our data from control subjects also confirm previous reports in
which smoking history was associated with significant increases in
MN frequencies [12,13,19] and primary DNA lesions [20].
Interestingly, we did not observe the same effect in smoker/ex-
smoker UCC patients. Thus, as previously proposed [21], we
suggest that the pathological status may mask the effects of
cigarette smoking on MNC frequency. Cigarette smoking has also
been associated with other genetic alterations found in bladder
cancer patients. TP53 mutations, TP16 promoter hypermethyla-
tion, and the overexpression of various oncogenes and growth
factors have been detected in tumor and normal tissues from
patients with a history of smoking [22–25]. Furthermore, increases
in p53 protein levels were observed in the normal urothelium of
current and previous smokers [26]. Therefore, in urothelial cells,
mutations or other alterations in the p53 pathway caused by
cigarette smoking could be involved in the high MNC frequencies
observed in our study as well as the increased risk of bladder
cancer development and recurrence [12,13,19,20].
Few studies have addressed the aneugenic or clastogenic effects
of cigarette smoking in target and surrogate cells. The available
data have shown a trend towards no differences between these 2
mechanisms of MN formation [27]. Despite the relatively small
sample size, especially after stratification into subgroups, our data
demonstrate that subjects with a history of UCC harbor and
accumulate genetically unstable cells in the bladder urothelium
that may represent early precursors of new UCC or subclones
from previous UCC. Furthermore, we showed that the majority of
MN detected in urothelial cells arose from chromosomal breakage.
Therefore, micronucleus test may provide an informative auxiliary
biomarker to monitor bladder cancer.
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combined analysis of XRCC1, XRCC3, GSTM1 and GSTT1 polymorphisms
and centromere content of micronuclei in welders. Mutagenesis 21: 159–165.
Genetic Instability in Patients with UCC
PLOS ONE | www.plosone.org 6 January 2014 | Volume 9 | Issue 1 | e86162
